Dr Leighl on Amivantamab in Advanced NSCLC With MET Exon 14 Skipping Mutations
September 12th 2023Natasha B. Leighl, BSc, MMSc, MD, discusses efficacy findings with the EGFR/MET inhibitor amivantamab in patients with advanced non–small cell lung cancer harboring MET exon 14 skipping mutations.
Read More